Loading page
Loading page
Loading substance route
Administered as blotter tabs or liquid held under the tongue. The NBOMe series exhibits highly variable individual sensitivity; conservative dosing from lower range is strongly recommended.
Rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration, mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor attenuated these reinforcing effects.
Vasoconstriction is a noted effect that at high doses can potentially endanger life; users should exercise particular caution with dosing.
25E-NBOMe first appeared in scientific literature around 2012, emerging as part of the broader NBOMe series of substituted phenethylamines. This class of compounds, which includes related substances such as 25I-NBOMe and 25C-NBOMe, gained attention during this period as novel psychoactive substances. Following its initial scientific documentation, 25E-NBOMe subsequently appeared on the recreational drug market alongside other members of this chemical family.
Classified as a narcotic substance by Sweden's public health agency on January 18, 2019. This classification places it under the same regulatory framework as other controlled narcotics in Swedish law.
Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause. Class A substances carry the most severe penalties, with possession punishable by up to 7 years imprisonment and supply offenses carrying maximum life sentences.